SCHEMBL22895754

SCHEMBL22895754

Clc1ncc(Cl)c(Oc2ccccc2)n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 7/20 0.64
POLB P06746 2/20 0.45
CASP6 P55212 1/20 0.45
HTT P42858 3/20 0.44
ALDH1A1 P00352 2/20 0.44
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
LMNA P02545 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TSHR P16473 2/20 0.42
CYP2C9 P11712 1/20 0.42
APEX1 P27695 1/20 0.42
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
NPC1 O15118 1/20 0.41
GAA P10253 1/20 0.41
RAB9A P51151 1/20 0.41
HRH4 Q9H3N8 1/20 0.40
MAPT P10636 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29596360 1.00 PIN1 (0.64) PIN1POLBCASP6HTTALDH1A1
SCHEMBL17792853 0.83 PIN1 (0.64) PIN1POLBCASP6HTTALDH1A1
SCHEMBL31547647 0.82 PIN1 (0.60) PIN1POLBCASP6HTTALDH1A1
SCHEMBL29041274 0.82 PIN1 (0.60) PIN1POLBCASP6HTTALDH1A1
SCHEMBL13068257 0.82 POLB (0.47) PIN1POLBCASP6ALDH1A1CRHBP
SCHEMBL17544398 0.82 PIN1 (0.60) PIN1POLBCASP6HTTALDH1A1
SCHEMBL12620334 0.82 PIN1 (0.60) PIN1POLBCASP6HTTALDH1A1
SCHEMBL1863316 0.82 SMN1; SMN2 (0.47) PIN1POLBCASP6HTTALDH1A1
SCHEMBL22911840 0.82 BCL6 (0.49) PIN1HTTALDH1A1CRHBPCRHR2
SCHEMBL8491495 0.81 PIN1 (0.48) PIN1ALDH1A1SMN1; SMN2TSHRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240409609-A1 REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF TERREMOTO BIOSCIENCES, INC. 2024-12-12 US disclosed
WO-2023070114-A2 REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2023-04-27 WO disclosed
WO-2023070114-A2 REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2023-04-27 WO disclosed
US-20220388990-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES KINNATE BIOPHARMA INC. 2022-12-08 US disclosed
US-20220388990-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES KINNATE BIOPHARMA INC. 2022-12-08 US disclosed
US-11390618-B2 Inhibitors of cyclin-dependent kinases KINNATE BIOPHARMA INC. (US) 2022-07-19 US disclosed
US-11358958-B2 2022-06-14 US disclosed
US-11358958-B2 2022-06-14 US disclosed
EP-3999498-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES Kinnate Biopharma Inc. (US) 2022-05-25 EP disclosed
CN-114401955-A Inhibitors of cyclin dependent kinases 金耐特生物制药公司 2022-04-26 CN disclosed
US-20210130340-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES KINNATE BIOPHARMA INC. 2021-05-06 US disclosed
US-20210130340-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES KINNATE BIOPHARMA INC. 2021-05-06 US disclosed
EP-3813819-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES Kinnate Biopharma Inc. (US) 2021-05-05 EP disclosed
CN-112638373-A Cyclin-dependent kinase inhibitors 金耐特生物制药公司 2021-04-09 CN disclosed
WO-2021011796-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES KINNATE BIOPHARMA INC. (US) 2021-01-21 WO disclosed
WO-2021011796-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES KINNATE BIOPHARMA INC. (US) 2021-01-21 WO disclosed
US-10894788-B2 Inhibitors of cyclin-dependent kinases KINNATE BIOPHARMA INC. (US) 2021-01-19 US disclosed
US-10894788-B2 Inhibitors of cyclin-dependent kinases KINNATE BIOPHARMA INC. (US) 2021-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11358958-B2 CDK2, CDK1, CDK6 PIN1 1249/4885POLB 319/4885CASP6 1061/4885
US-20210130340-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK2, CCNK, CDK1 PIN1 1040/4885POLB 561/4885CASP6 1857/4885
US-10894788-B2 Inhibitors of cyclin-dependent kinases CDK2, CCNK, CDK1 PIN1 1040/4885POLB 561/4885CASP6 1857/4885
US-20240409609-A1 REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF EGFR, ERBB2, ERBB3 PIN1 2060/4885POLB 3444/4885CASP6 4319/4885
US-20220388990-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK2, CCNK, CDK1 PIN1 822/4885POLB 504/4885CASP6 1688/4885
US-11390618-B2 Inhibitors of cyclin-dependent kinases CDK2, CCNK, CDK1 PIN1 1040/4885POLB 561/4885CASP6 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.